Changes in Hong Kong stocks | Yasheng Pharmaceutical-B (06855) rose nearly 4% BTK degrading agent APG-3288 new drug clinical application approved by US FDA

Zhitongcaijing · 4d ago

The Zhitong Finance App learned that Yasheng Pharmaceutical-B (06855) rose nearly 4%. As of press release, it had risen 3.69% to HK$53.4, with a turnover of HK$61.6418 million.

According to the news, on January 7, Yasheng Pharmaceutical's official WeChat announced that the new drug clinical application (IND) for APG-3288, an innovative generation BTK-targeted proteolytic agent, has been approved by the US FDA to carry out clinical research on the treatment of relapsed/refractory B-cell malignancies. This marks that the company's research and development results in the field of targeted protein degradation have officially entered the clinical stage. It is another major layout of Yasheng Pharmaceutical's global innovation pipeline. The study is a global multi-center, open phase I clinical study to evaluate the safety, tolerability, PK characteristics and initial efficacy of APG-3288 in patients with relapsed/refractory hematologic malignancies.